Kromasil introduces a purification toolbox for GLP-1 agonists
With the number of people around the world diagnosed with diabetes increasing, the need for adequate treatments are also on the rise. Many of the substances used in production of this type of pharmaceuticals are peptides and have been found challenging to purify, in an efficient way, to the level needed to be approved for safe use by patients. This is where Kromasil's high performing chromatography media now supports the pharmaceutical industry.
“With our efficient purification strategy, it is possible to reach the 99.5 % purity needed for regulatory approval in only two steps compared to three or four steps, which is often the case in the industry today. This translates into greatly improved efficiency and productivity for our customers, said Patrick Wilhelm,” Vice President of Inorganic Specialties at Nouryon.
The new purification toolbox for GLP-1 (glucagon-like peptide-1) agonists such as liraglutide, enables tailor made solutions to the different conditions in our customers production processes and includes procedures that greatly improve the Kromasil media lifetime by increasing the number of purification cycles that can be carried out. This enables our customers to significantly reduce the time needed to optimize their purification process and as a result, a more efficient process.
“Type 2 diabetes patients rely on their medicine every day and, in many cases, it’s a lifelong treatment. We are proud to be able to provide our pharmaceutical customers with solutions that contribute to the promotion of well-being to ensure healthy lives,” said Wilhelm.
To learn more, download our brochure, listen to how our scientists talk about it or get in touch with us:Get the presentation folder How our people talk about it (Youtube movie) Contact us